Alumis (ALMS) Profit After Tax (2023 - 2026)
Alumis (ALMS) posted quarterly Profit After Tax of -$324.9 million for Q4 2025, down 242.84% year-over-year from $227.4 million in Q4 2024, and down 193.33% quarter-over-quarter from -$110.8 million in Q3 2025.
Alumis (ALMS) Profit After Tax (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Profit After Tax for 3 consecutive years, with -$324.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Profit After Tax fell 242.84% year-over-year to -$324.9 million; the TTM figure through Dec 2025 stood at -$475.3 million (down 38.65% YoY), while the FY2025 annual figure was -$475.1 million, down 61.46% from the prior year.
- Profit After Tax slipped to -$324.9 million in Q4 2025 per ALMS's latest filing, from -$110.8 million in the prior quarter.
- Across five years, Profit After Tax topped out at $59.3 million in Q2 2025 and bottomed at -$324.9 million in Q4 2025.
- Historically, Profit After Tax has averaged -$85.2 million across 3 years, with a median of -$56.5 million in 2024.
- On a YoY basis, Profit After Tax climbed as much as 204.98% in 2025 and fell as far as 242.84% in 2025.
- Alumis' Profit After Tax stood at -$39.3 million in 2023, then sank by 141.07% to -$94.8 million in 2024, then plunged by 242.84% to -$324.9 million in 2025.
- Business Quant data shows ALMS's Profit After Tax at -$324.9 million in Q4 2025, -$110.8 million in Q3 2025, and $59.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - | -142.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -142.44 Mn |
| Dec 31, 2025 | -324.87 Mn |
| Sep 30, 2025 | -110.75 Mn |
| Jun 30, 2025 | 59.32 Mn |
| Mar 31, 2025 | -98.96 Mn |
| Dec 31, 2024 | -94.76 Mn |
| Sep 30, 2024 | -141.67 Mn |
| Jun 30, 2024 | -56.51 Mn |
| Mar 31, 2024 | -49.85 Mn |
| Dec 31, 2023 | -39.31 Mn |
| Sep 30, 2023 | -43.38 Mn |
| Jun 30, 2023 | -36.29 Mn |